目录产品 » IL-8/CXCL8, His, Cynomolgus

IL-8/CXCL8, His, Cynomolgus

Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.Several promising approaches that target directly or indirectly IL-8 effects in gliomas are currently in progress while more-in-depth studies are needed to validate its biomarker role and elucidate the underlying molecular mechanisms.
¥3500
Z04847-100

Species Cynomolgus
Protein Construction
IL-8/CXCL8 (Ala23-Pro100)
Accession # A0A2K5TUL7
His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized IL-8/CXCL8, His, Cynomolgus at 1μg/ml (100μl/well) on the plate can bind Anti­IL­8 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 10.12 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 12-14 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

IL-8/CXCL8, His, Cynomolgus

Immobilized IL-8/CXCL8, His, Cynomolgus, His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for Anti-IL-8 Antibody, hFc Tag with the EC50 of 4.9 ng/ml determined by ELISA. »

IL-8/CXCL8, His, Cynomolgus

IL-8/CXCL8, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Target Background Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.Several promising approaches that target directly or indirectly IL-8 effects in gliomas are currently in progress while more-in-depth studies are needed to validate its biomarker role and elucidate the underlying molecular mechanisms.
Synonyms Interleukin-8; IL-8; GCP-1; MDNCF; MONAP; NAP-1; GCP/IL-8 protein IV; IL8/NAP1 form I; CXCL8; LECT; LUCT; LYNAP; NAF
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.